Radar · Infectious Diseases in New York
Best Infectious Diseases Companies in New York, United States
The 61 best Infectious Diseases companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Everest Medicines.
By Riya SenguptaFinancials
61companies tracked
$1.3Bdisclosed funding
0unicorns
39have raised
FLIAR INTELLIGENCE · INFECTIOUS DISEASES × NEW YORK
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
59%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2014median founding year
67kcombined LinkedIn audience
55%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Infectious Diseases companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Everest Medicines Developer of drugs for the treatment of cancer | $593M | 73 mo ago | 395 | Kerry Blanchard CEO | — | 3 partnerships |
| 2 | SIGA Technologies Developer of anti-infective therapeutics for bio-warfare threats | $248M | 115 mo ago | 39 | — | 287 patents Antiviral small‑molecule synthesis and oral/liquid formulation of Tecovirimat | — |
| 3 | Elion Therapeutics Developer of therapeutics for invasive fungal infections | $81M | 24 mo ago | — | Kieren Marr Co-Founder | — | 1 job opening |
| 4 | ILiAD Biotechnologies Developer of immunity-inducing vaccine for the prevention and treatment of pertussis 24Funding top 25%Moat top 36%Patents top 38%Innovation top 42% All 9 signals ▾Fundingtop 25% Moattop 36% Patentstop 38% Innovationtop 42% Newsbottom 49% Talentbottom 49% Globalbottom 36% Marketbottom 24% Techbottom 22% Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $51M | 5 mo ago | 8 | Keith Rubin Founder & CEO | 24 patents Patents concentrated in health & consumer products | 1 partnership |
| 5 | Codagenix Developer of live-attenuated viral vaccines using proprietary SAVE technology 62Patents top 19%Moat top 21%Innovation top 24%Talent top 28% All 9 signals ▾Patentstop 19% Moattop 21% Innovationtop 24% Talenttop 28% Fundingtop 30% Marketbottom 49% Globalbottom 42% Techbottom 38% Newsbottom 27% Patents: 127 patents matched (strict assignee match) · 91 filings since 2022 vs 36 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 127 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $47M | 14 mo ago | 41 | — | 127 patents Live-attenuated viral vaccine design using codon deoptimization and recombinant virus platforms | — |
| 6 | ContraFect Developer of therapeutics for the treatment of antibiotic-resistant infections | $39M | 70 mo ago | 23 | Roger Pomerantz CEO | 316 patents Passive influenza antibodies and bacteriophage lysin‑antimicrobial peptide therapeutics | — |
| 7 | Indaptus Developer of immunotherapies for oncology and infectious diseases 19Funding top 35%Moat top 39%Talent bottom 49%Growth bottom 42% All 7 signals ▾Fundingtop 35% Moattop 39% Talentbottom 49% Growthbottom 42% Globalbottom 30% Marketbottom 24% Newsbottom 23% Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $38M | 12 mo ago | 6 | Jeffrey Meckler Chief Executive Officer | — | — |
| 8 | Valthos Developer of AI systems for biological threat identification and countermeasure design 55Funding top 34%AI top 45%Talent bottom 49%Global bottom 33% All 4 signals ▾Fundingtop 34% AItop 45% Talentbottom 49% Globalbottom 33% Funding: Raised $30.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 55/100 | $30M | 10 mo ago | — | Tess Stekelenburg Co-Founder & President | — | — |
| 9 | RenBio Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases | $29M | 22 mo ago | 10 10 → 8 (-20%) | David Ho Co-Founder | 11 patents Gene therapy delivery devices and plasmid expression vectors for therapeutic proteins/peptides | — |
| 10 | Varro Life Sciences Developer of a technology to detect infectious agents in breath and air | $20M | 20 mo ago | — | Tom Cirrito Co-Founder & CEO | — | 1 partnership |
| 11 | Lodo Therapeutics Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | $20M | 114 mo ago | 24 | Sean Brady Co-Founder | — | — |
| 12 | Autonomous Therapeutics Developer of drugs for influenza & other infectious diseases treatment | $17M | 15 mo ago | 21 | Ariel Weinberger Co-Founder & CEO | — | — |
| 13 | Jan Biotech Provider of diagnostic assays for the detection of infectious diseases 10Funding top 42%Talent bottom 45%Tech bottom 34%Global bottom 29% All 5 signals ▾Fundingtop 42% Talentbottom 45% Techbottom 34% Globalbottom 29% Marketbottom 14% Funding: Raised $13.4M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 10/100 | $13M | 10 mo ago | 6 | Jennifer Nichols President/Co-Founder | — | — |
| 14 | CastleVax Developer of vaccines to treat infectious diseases | $8M | 32 mo ago | — | Matthew Stober CEO | — | — |
| 15 | Acurx Pharmaceuticals Developing antibiotics for priority pathogens, addressing critical global health needs | $8M | 77 mo ago | 4 | David Luci CEO | — | 1 partnership |
| 16 | INT Developer of diagnostic food safety devices | $6M | 111 mo ago | 15 | Michael Connolly CEO | — | — |
| 17 | Archean Biologics Developer of therapeutics for influenza | $4M | 61 mo ago | 6 | Christian Rudder Co-Founder | — | — |
| 18 | Tonix Pharma Developer of next-generation medicines for CNS and immunological disorders | $4M | 15 mo ago | 117 117 → 169 (+44%) | — | — | — |
| 19 | Exavir Developer of therapeutics for the treatment of viral diseases | $4M | 34 mo ago | 3 | Howard Gendelman Co-Founder | — | — |
| 20 | Helocyte Developing immunotherapies for cancer and infectious diseases, particularly cytomegalovirus | $4M | 116 mo ago | 2 | — | — | — |
| 21 | Voltron Therapeutics Develoepr of therapeutics to treat covid-19 and cancer | $3M | 44 mo ago | — | Patrick Gallagher CEO | — | — |
| 22 | OyaGen Drug discovery and development for infectious diseases and cancer therapeutics | $3M | 14 mo ago | 4 | Harold Smith founder and CEO of OyaGEn | 55 patents Antiviral small‑molecule therapeutics targeting viral replication enzymes and entry mechanisms | — |
| 23 | POP BIO Developer of nanomedicines to treat oncology and infectious diseases | $2M | 13 mo ago | 5 | Jonathan Smyth Co-Founder | — | — |
| 24 | Arcturus Developer of messenger RNA medicines and vaccines for infectious diseases | $2M | 64 mo ago | 4 | Ben Salander Co-Founder | 2 patents mRNA cap analogs for therapeutics; modular AI knowledge representation and sharing systems | — |
| 25 | Mercia Pharma Vaccine in combination with adjuvants for autoimmune, CNS, respiratory and infectious diseases | $2M | 204 mo ago | — | Peter Blackburn President and Founder | — | — |
| 26 | Reme-D.Inc Developer of diagnostic kits for both human and animal diseases 27Patents top 30%Global top 38%Innovation top 41%Funding top 44% All 7 signals ▾Patentstop 30% Globaltop 38% Innovationtop 41% Fundingtop 44% Talentbottom 49% Techbottom 30% Marketbottom 25% Patents: 42 patents matched (strict assignee match) · 10 filings since 2022 vs 6 in 2017-21 Global: Patents filed in 3 jurisdictions · Investors from 3 countries beyond United States rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 2 mo ago | — | Salma Tammam Founder & CEO | 42 patents Hydraulic control valves and pistons for rotary steerable drilling tools | — |
| 27 | Symbiotic Health Develops microbiome-based therapeutics for gastrointestinal infection | $1M | 116 mo ago | 7 | Gerard Honig CEO and Founder | — | — |
| 28 | Chronus Pharmaceuticals Developing diagnostics and therapeutics for infectious diseases through innovative technologies | $750K | 71 mo ago | — | Peter Tonge Co-Founder | — | — |
| 29 | Assembly Biosciences Developing novel antivirals to treat serious viral diseases | $700K | 18 mo ago | 169 169 → 99 (-41%) | Atul Kumar Founder & Managing Director | 317 patents Antiviral heterocyclic small‑molecule therapeutics and crystalline forms for herpes infections | 1 launch |
| 30 | Epitor Therapeutics Developer of therapeutics based on gene editing technologies | $698K | 21 mo ago | — | Megan McGill CEO | — | — |
| 31 | Ionica Sciences Online slot platform offering diverse games and trusted maxwin server | $629K | 67 mo ago | 2 | Omar Green CEO | — | — |
| 32 | Ichor Biologics Developer of monoclonal antibodies for treating infectious and inflammatory diseases | $300K | 85 mo ago | 21 | Raymond Alvarez Co-Founder & CEO | 6 patents Therapeutic antibodies for Andes hantavirus detection and treatment | — |
| 33 | Calder Biosciences Developer of influenza vaccines | $275K | 33 mo ago | 7 | Christopher P Marshall Founder & CEO | 43 patents Stabilized RSV pre‑fusion F protein antigens for pediatric vaccine development | — |
| 34 | Lab11 Therapeutics Developer of anti-viral drugs to treat viral infections | $256K | 58 mo ago | 2 | — | — | — |
| 35 | A2A Pharmaceuticals AI-driven pharmaceutical company developing novel drug alternatives for life-threatening diseases | $250K | 116 mo ago | 4 | Edward Painter Founder | — | — |
| 36 | Guanine Developer of diagnostic test for the detection of infectious diseases | $225K | 106 mo ago | — | Neil Gordon President & CEO | — | — |
| 37 | Bioharmony Therapeutics Company developing lysin based therapeutics for treating infectious diseases caused by bacteria | $100K | 102 mo ago | 1 | Chandrabali Ghose Founder & CEO | — | — |
Top 12 Infectious Diseases companies in New York
#1
Series B · New York City, New York · founded 2012 · 8 employees$51.2Mraised▾
Series B · New York City, New York · founded 2012 · 8 employees
Developer of immunity-inducing vaccine for the prevention and treatment of pertussis. Its lead candidate BPZE1, a live attenuated Bordetella pertussis (BP) vaccine claims to induce sterilizing mucosal immunity and long-lasting protection against pertussis disease. The candidate is nasally administered BPZE to induce both mucosal and systemic potent immune responses.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 25%Moat
top 36%Patents
top 38%Innovation
top 42%News
bottom 49%Talent
bottom 49%Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) · Last round Series B (Feb 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents · Soonicorn
Patents: 24 patents matched (strict assignee match) · 18 filings since 2022 vs 1 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 2k LinkedIn followers — 2.9% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. hVIVO) announced in 12 mo
Funding rounds
- Feb 2026Series B$115M
- Dec 2023Series A—
- Sep 2022Series A$42.8M
- May 2022Grant (prize money)$972.1K
Founders & team
Investors
Livent, Knottpartners, NIH, HHS, RA Capital Management, Janus Henderson Investors
#2
Seed · New York, New York · founded 2024$30Mraised▾
Seed · New York, New York · founded 2024
Developer of AI systems for biological threat identification and countermeasure design. It builds advanced artificial intelligence to detect biological risks in real time. The company also engineers medical solutions to combat these identified threats. It aims to provide next-generation biodefense capabilities through its technological developments.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 34%AI
top 45%Talent
bottom 49%Global
bottom 33%Funding: Raised $30.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Aug 2025)
AI: Product described with: artificial intelligence
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 3k LinkedIn followers — 5.1% of this cohort's audience
Funding rounds
- Aug 2025Seed$30M
Founders & team
Investors
OpenAI Startup Fund, Lux Capital, Founders Fund
#3
Series B · Stony Brook, New York · founded 2011 · 41 employees$47.1Mraised▾
Series B · Stony Brook, New York · founded 2011 · 41 employees
Developer of live-attenuated viral vaccines using proprietary SAVE technology. The SAVE platform relies on synthetic biology and re-design of the target virus' entire genome to yield a vaccine strain. All pipeline vaccines are currently in preclinical stages targeting seasonal influenza, dengue virus (DEV), respiratory syncytial virus (RCV), and pandemic influenza.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 19%Moat
top 21%Innovation
top 24%Talent
top 28%Funding
top 30%Market
bottom 49%Patents: 127 patents matched (strict assignee match) · 91 filings since 2022 vs 36 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 7/10 · IP moat: 127 patents
Innovation: 127 patents (top 22% of patent-holders) · 91 filings since 2022 vs 36 in 2017-21
Funding rounds
- Apr 2025Grant (prize money)$4.4M
- Oct 2023Grant (prize money)$10M
- Feb 2023Series B$25M
- Jul 2020Grant (prize money)$4.8M
Investors
Adjuvant Capital, Topspin Fund, Euclidean Capital, Serum Institute of India, HHS, NIH
Tech stack
WordpressMysqlPhpGenesis ThemeContact Form 7Yoast Seo
#4
Public · New York City, New York · founded 2021 · 6 employees$37.9Mraised▾
Public · New York City, New York · founded 2021 · 6 employees
Developer of immunotherapies for oncology and infectious diseases. The lead candidate Decoy20 provides broad anti-tumor and anti-viral responses in combination for the treatment of colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin’s lymphoma.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Funding
top 35%Moat
top 39%Talent
bottom 49%Growth
bottom 42%Global
bottom 30%Market
bottom 24%Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Post IPO (Jun 2025)
Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 1k LinkedIn followers · 24 engagements/post (2.1× cohort median)
Funding rounds
- Jun 2025Post IPO$5.7M
- Jan 2025Post IPO$2.2M
- Jul 2021Post IPO$30M
Founders & team
#5
Funding Raised · Ithaca, New York · founded 2014 · 6 employees$13.4Mraised▾
Funding Raised · Ithaca, New York · founded 2014 · 6 employees
Provider of diagnostic assays for the detection of infectious diseases. The company offers novel molecular in vitro assays for clinical diagnosis and quantification of latent infections such as HIV-1, as well as detection of aggressive cancer (ex., prostate) and cancer treatment monitoring.
Fliar Intelligence Index™ 10how this company ranks against its industry peers
Funding
top 42%Talent
bottom 45%Tech
bottom 34%Global
bottom 29%Market
bottom 14%Funding: Raised $13.4M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) · Last round Grant (prize money) (Aug 2025)
Talent: 1 named leader on record
Tech: 15 technologies across 2/8 capability areas · Cloud: Cloudflare · Security: Http/3
Funding rounds
- Aug 2025Grant (prize money)$3.3M
- Feb 2025Grant (prize money)$300K
- Feb 2025Grant (prize money)$3.3M
- Sep 2023Grant (prize money)$300K
Founders & team
Investors
HHS
Tech stack
WordpressMysqlPhpBootstrapVimeoYoast Seo
#6
Seed · New York City, New York · founded 2022$1.5Mraised▾
Seed · New York City, New York · founded 2022
Developer of diagnostic kits for both human and animal diseases. It offers kits for nucleic acid extraction, amplification, sequencing, and detection to diagnose both infectious and non-infectious diseases.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Patents
top 30%Global
top 38%Innovation
top 41%Funding
top 44%Talent
bottom 49%Tech
bottom 30%Patents: 42 patents matched (strict assignee match) · 10 filings since 2022 vs 6 in 2017-21 · Latest publication 2024
Global: Patents filed in 3 jurisdictions · Investors from 3 countries beyond United States
Innovation: 42 patents (top 52% of patent-holders) · 10 filings since 2022 vs 6 in 2017-21
Audience (LinkedIn): 5k LinkedIn followers — 8.1% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. Egypt's Governmental Health Sector and all UPA customers) announced in 12 mo
Funding rounds
- Apr 2026Seed$500K
- Nov 2023Grant (prize money)$10K
- Seed$1M
Founders & team
Investors
Visa, CIB Egypt, Global Innovation Fund, Oman Tech Fund
Tech stack
All In One SeoApache Http ServerBootstrapContact Form 7Core-JsElementor
#7
Funding Raised · New York City, New York · founded 2017 · 21 employees$16.8Mraised▾
Funding Raised · New York City, New York · founded 2017 · 21 employees
Autonomous Therapeutics is a developer of drugs for influenza & other infectious diseases treatment. It has developed a therapeutic platform against infectious diseases and cancer.
Funding rounds
- Apr 2025Grant (prize money)$6.4M
- May 2024Grant (prize money)$273.6K
- Apr 2020Grant (prize money)$5.7M
- Jun 2017Grant (prize money)$4.5M
Founders & team
Investors
HHS, JLABS
#8
Series A · New York City, New York · founded 2016 · 10 employees$29.2Mraised▾
Series A · New York City, New York · founded 2016 · 10 employees
Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases. The company's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint & antibody factory.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers — 3.0% of this cohort's audience
Funding rounds
- Aug 2024Series A$5.2M
- Jan 2021Series A$24M
- Jul 2016Grant (prize money)$3.4M
Founders & team
Investors
Ruentex Industries, Military Health
Tech stack
WordpressMysqlPhpWp RocketNginxJquery Migrate
#9
Public · New York City, New York · founded 2007 · 117 employees$4.5Mraised▾
Public · New York City, New York · founded 2007 · 117 employees
Developer of next-generation medicines for CNS and immunological disorders. The lead product of the company is TNX-601 (tianeptine oxalate), for the treatment of Post-traumatic stress disorder (PTSD), and TNX-801 for horsepox virus.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 23k LinkedIn followers — 34.7% of this cohort's audience
Funding rounds
- Apr 2025Grant (prize money)$5.2M
- Feb 2025Grant (prize money)$5.2M
- Oct 2022Post IPO$15M
- Aug 2022Grant (prize money)—
Investors
Technology Partners, NIH, HHS, Westwicke
Tech stack
Animate.CssApache Http ServerBootstrapBrowser-Update.OrgContact Form 7Cookieyes
#10
Seed · New York City, New York · founded 2020$20Mraised▾
Seed · New York City, New York · founded 2020
Developer of a technology to detect infectious agents in breath and air. It offers a biodetector devices that combines microbiology, aerosols engineering, and advanced electronics for real-time detection of respiratory pathogens.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 900 LinkedIn followers
Hiring: 1 hiring post in 12 mo (public) · hiring: Senior Scientist, Electrochemistry
Activity: 1 partnerships · 1 awards (incl. CIC) announced in 12 mo
Funding rounds
- Oct 2024Angel$20M
Founders & team
#11
Seed · Rochester, New York · founded 2003 · 4 employees$2.8Mraised▾
Seed · Rochester, New York · founded 2003 · 4 employees
Drug discovery and development for infectious diseases and cancer therapeutics. The company focuses on identifying novel therapeutic indications and IND-enabling lead compounds for licensing or partnering. Their expertise spans assay development, screening, and mechanistic studies, offered as a fee-for-service. They develop antiviral and oncology therapeutics, targeting mechanisms responsible for tumor growth and progress. The company seeks collaborators for assay development and drug discovery services, aiming to deliver new therapeutic solutions for clinical development and commercialization. They have High Content Screening (HCS) aspirations and plan to expand screening capabilities. Their lead compounds address HIV, Ebola, and COVID-19. They are involved in preclinical drug discovery, lead compound optimization, and offer services in cell biology, virology, and structural biology. They are based on assay development technology and academic work on gene editing enzymes.
Funding rounds
- May 2025Grant (prize money)$597K
- Aug 2023Grant (prize money)$597K
- Jul 2020Grant (prize money)$572.9K
- Aug 2018Grant (prize money)$600K
Founders & team
Investors
HHS
Tech stack
WordpressMysqlPhpTwenty ThirteenNginxGravity Forms
#12
Series B · New York City, New York · founded 2024$81Mraised▾
Series B · New York City, New York · founded 2024
Developer of therapeutics for invasive fungal infections. It offers a lead candidate SF001 for IV infusion which comprises a micellar solution of Sfu-AM2-19A, a polyene compound used for the treatment of aspergillosis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers — 2.3% of this cohort's audience
Hiring: 5 hiring posts in 12 mo (public) · momentum -3 · hiring: Project Manager, contract clinical supplies manager
Funding rounds
- Jun 2024Series B$81M
Founders & team
Investors
Deerfield, AMR Action Fund, Illinois Ventures
Funding & investor landscape
$1.3Btotal disclosed funding
39companies funded
148disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Keith Rubin
Founder & CEO · ILiAD Biotechnologies
Tess Stekelenburg
Co-Founder & President · Valthos
Jeffrey Meckler
Chief Executive Officer · Indaptus
Jennifer Nichols
President/Co-Founder · Jan Biotech
Salma Tammam
Founder & CEO · Reme-D.Inc
Ariel Weinberger
Co-Founder & CEO · Autonomous Therapeutics
Leor Weinberger
Co-Founder · Autonomous Therapeutics
David Ho
Co-Founder · RenBio
Yaoxing Huang
Co-Founder · RenBio
Tom Cirrito
Co-Founder & CEO · Varro Life Sciences
David Shuler
Co-Founder · Varro Life Sciences
Harold Smith
founder and CEO of OyaGEn · OyaGen
Prism market signals · United States · country-scoped Prism corpus, 1,265,774 docs
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
RESEARCH SIGNALS · United States
How research on Diagnostics is moving in the United States
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,526 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 53% → 57% across 2008–2026.
top research entities
- Harvard University330
- Johns Hopkins University318
- Heidelberg University249
- Massachusetts General Hospital214
- The University of Texas MD Anderson Cancer Center191
leading researchers
Gerald J. Kost · Liya Xu · Charlotte A. Gaydos · Andrew A. Davis · Yu‐Hsiang Hsieh · Stephanie N. Shishido · Helen J. Huang · David T. Wong
▲
Breakthroughs1,879 · 22%
▲ 18%→24% share
▲1.3× share momentum1 median citations56% since 2021mostly methods-led
Liquid biopsy breakthroughs are surging — U.S. diagnostic papers tripled from 125 to 427, now anchoring 24% of breakthrough research.
rising sub-themes (early→recent)
- Liquid biopsy125→427
- Biopsy15→114
- Biomarker17→103
- Point-of-care testing112→195
- Cancer67→146
Newly emergingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→58 · Coronavirus disease 2019 (COVID-19) 0→45 · Methylation 0→33
Landmark Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells · 1,071 cites
◆
Advancements3,687 · 43%
▲ 39%→45% share
▲1.2× share momentum2 median citations54% since 2021mostly empirical
Cancer diagnostics advancements are intensifying — liquid biopsy advancement papers quadrupled (183->739) alongside newly emerging precision oncology and glioblastoma sub-topics.
rising sub-themes (early→recent)
- Liquid biopsy183→739
- Biopsy42→285
- Biomarker55→208
- Cancer115→260
- Oncology57→183
Newly emergingTranscriptome 0→19 · Glioblastoma 0→18 · Precision oncology 0→16
Landmark Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies · 5,005 cites
▼
Concerns2,138 · 25%
▼ 32%→22% share
▼0.7× share momentum7 median citations45% since 2021mostly empirical
Concern-flagged diagnostics research is cooling in field-share (32%->22%) despite liquid biopsy concerns nearly quadrupling (67->239) and COVID-19 newly emerging.
rising sub-themes (early→recent)
- Liquid biopsy67→239
- Biopsy17→99
- Biomarker28→86
- Coronavirus disease 2019 (COVID-19)1→44
- Cancer55→92
Newly emergingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→40 · Extracellular vesicles 0→21 · Glioma 0→11
Landmark Point-of-Care Diagnostics for Global Health · 1,066 cites
RESEARCH HOTSPOTS · United States
Where diagnostics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston642 · +0.40
New York419 · +0.36
SF Bay Area370 · +0.36
Los Angeles278 · +0.50
Philadelphia194 · +0.30
Chicago182 · +0.40
Seattle166 · +0.34
San Diego165 · +0.43
Atlanta127 · +0.28
Ann Arbor108 · +0.47
PATENT SIGNAL · United States
Who's filing diagnostics patents in the United States
United States diagnostics patent filing is accelerating — 418 filings from 196 assignees (2016–2025), led by Detect, UNIV Leland Stanford Junior, Texas A & M UNIV SYS; annual filings 13→55.
418 filings196 assigneespeak 67/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Detect42
- UNIV Leland Stanford Junior34
- Texas A & M UNIV SYS20
- Washington University ST Louis20
- Nuclein19
- UNIV California19
- Tempus LABS18
- New England Biolabs18
Common questions
How many Infectious Diseases companies are there in New York, United States?
Radar tracks 61 indexable Infectious Diseases companies headquartered in New York, United States that meet our profile-completeness bar.
What is the total funding raised by Infectious Diseases companies in New York, United States?
The Infectious Diseases companies in New York, United States on this list have raised a combined $1.3B in disclosed equity funding across 39 funded companies.
Which is the highest-funded Infectious Diseases company in New York, United States?
Everest Medicines is the highest-funded Infectious Diseases company in New York, United States, with $593M in disclosed equity funding.
How many Infectious Diseases companies in New York, United States are funded?
39 of the 61 Infectious Diseases companies in New York, United States on this list have disclosed at least one equity funding round.
How many Infectious Diseases unicorns are there in New York, United States?
None of the Infectious Diseases companies in New York, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in New York, United States Infectious Diseases companies?
The most active investors in New York, United States Infectious Diseases companies on this list include HHS, NIH, Design Technologies, Military Health, Harlem Biospace.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.